A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants
A Randomized, Double Blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Subcutaneous Administrations of SHR 3201 Injection in Healthy Participants
This study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous administrations of SHR-3201.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Yifei He, PhD.
- Número de telefone: +86-0518-82342973
- E-mail: yifei.he.yh91@hengrui.com
Estude backup de contato
- Nome: Yuanyuan Huang, PhD.
- Número de telefone: +86-0518-82342973
- E-mail: yuanyuan.huang@hengrui.com
Locais de estudo
-
-
Anhui
-
Hefei, Anhui, China, 230000
- Recrutamento
- The First Affiliated Hospital of University of Science and Technology of China
-
Investigador principal:
- Jiong Shi
-
Investigador principal:
- Zhaoyi Yang
-
Contato:
- Jiong Shi
- E-mail: jshi2022@ustc.edu.cn
-
Contato:
- Zhaoyi Yang
- Número de telefone: +86-551-65997421
- E-mail: young2382@ustc.edu.cn
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Healthy male or female participants aged 18 to 60 years (inclusive) at the time of informed consent signing;
- Male participants weighing ≥ 50.0 kg, and female participants weighing ≥ 45.0 kg, with a body mass index (BMI) between 19.0 and 28.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²);
- Female participants of child bearing potential shall agree to contraception and oocyte donation avoidance from ICF signature to 6 months after last investigational product dose, with negative serum pregnancy tests at screening and baseline. Male participants shall agree to highly effective contraception and sperm donation avoidance from ICF signature to 6 months after last investigational product dose;
- Ability to understand the study procedures and requirements, willingness to participate voluntarily, and provide written informed consent.
Exclusion Criteria:
- Participants with past or current acute or chronic disorders of the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric systems or metabolic abnormalities, as assessed by the Investigator to be unsuitable for study enrollment;
- Have a history of drug or other allergies, or, in the investigator's judgment, may be allergic to the investigational product or any of its components;
- Have undergone major surgery within 6 months prior to screening, or have undergone surgery that may significantly affect the in vivo disposition of the investigational product or the safety evaluation, or plan to undergo surgery during the trial period;
- Have participated in any clinical trial as a participant within 3 months prior to Screening, or plan to participate in other clinical trials during the course of this study;
- Have experienced blood loss or donated blood > 400 mL (excluding menstrual blood loss in females), received blood transfusion or blood products within 3 months prior to Screening, or plan to donate blood during the trial or within 1 month after the end of the trial;
- Cannot tolerate MRI or have MRI contraindications, including but not limited to cardiac pacemaker, defibrillator, artificial heart valve or other metallic implants; or other conditions assessed by the Investigator that may cause potential risks during MRI scanning;
- Have any laboratory abnormalities at screening, or have clinically significant abnormalities in vital signs, physical examinations, or laboratory tests specified in the protocol as judged by the investigator;
- Have chest X-ray (posteroanterior view) or abdominal ultrasound findings at Screening judged by the investigator to be clinically significant abnormalities;
- Have positive results at Screening for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), or Treponema pallidum antibody (Anti-TP);
- Have used or are currently using any prescription drugs or over-the-counter (OTC) medications within 2 weeks prior to dosing; or have taken functional vitamins, health supplements, or herbal products; or are known to require other medication during the trial period;
- Have consumed excessive amounts of tea, coffee, or caffeinated beverages (average > 8 cups per day, 200 mL per cup) within 3 months prior to screening;
- Have consumed special foods (e.g., grapefruit, grapefruit juice, or food/beverages containing grapefruit juice, chocolate, tobacco, alcohol, caffeinated products, etc.) within 48 hours prior to dosing;
- Have a history of regular alcohol consumption (i.e., > 14 standard units per week within 3 months prior to Screening, where 1 standard unit contains 14 g of alcohol, equivalent to 285 mL of beer, 25 mL of 40% spirit, or 85 mL of wine), or are unable to abstain from alcohol during the trial; or have a positive alcohol breath test;
- Have an average daily smoking history of > 5 cigarettes per day within 3 months prior to Screening, or are unable to abstain from smoking during the trial;
- Have a history of drug abuse or substance use; or have a positive result on drug abuse screening (including MDMA, methamphetamine, morphine, ketamine, and THC acid);
- Are pregnant or lactating females;
- Have difficulty with venous blood sampling, are unable to tolerate venipuncture, or have a history of needle or blood phobia;
- Participants who, in the opinion of the investigator, may be unable to complete the study for other reasons, or who are considered unsuitable for enrollment by the investigator.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Dose 1 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 1. |
SHR 3201 injection. SHR 3201 placebo. |
|
Experimental: Dose 2 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 2. |
SHR 3201 injection. SHR 3201 placebo. |
|
Experimental: Dose 3 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 3. |
SHR 3201 injection. SHR 3201 placebo. |
|
Experimental: Dose 4 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 4. |
SHR 3201 injection. SHR 3201 placebo. |
|
Experimental: Dose 5 Group: SHR-3201 + Placebo
SHR-3201, SHR-3201 Placebo, in Dose 5. |
SHR 3201 injection. SHR 3201 placebo. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Adverse events (AEs)
Prazo: From pre-dose to 36 days post-dose.
|
From pre-dose to 36 days post-dose.
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Serum concentration of SHR-3201 after single-dose administration
Prazo: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Area Under the Concentration (AUC) of SHR-3201 after single administration (AUC0-last, AUC0-inf)
Prazo: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Time to peak concentration (Tmax)
Prazo: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Peak concentration (Cmax)
Prazo: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Elimination half-life (T1/2)
Prazo: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Clearance (CL)
Prazo: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Steady-state volume of distribution (Vss)
Prazo: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Bioavailability of SHR-3201 following subcutaneous administration
Prazo: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
|
Incidence of anti-drug antibodies (ADA)
Prazo: From pre-dose to 29 days post-dose.
|
From pre-dose to 29 days post-dose.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- SHR-3201-101
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .